CN119548615A - 一种治疗方法 - Google Patents

一种治疗方法 Download PDF

Info

Publication number
CN119548615A
CN119548615A CN202411599223.4A CN202411599223A CN119548615A CN 119548615 A CN119548615 A CN 119548615A CN 202411599223 A CN202411599223 A CN 202411599223A CN 119548615 A CN119548615 A CN 119548615A
Authority
CN
China
Prior art keywords
seq
peptide
tlr7
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411599223.4A
Other languages
English (en)
Chinese (zh)
Inventor
S·塞勒米迪斯
D·A·布鲁克斯
J·欧莱里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Royal Melbourne Institute of Technology
Adelaide University
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Original Assignee
University of South Australia
Monash University
Royal Melbourne Institute of Technology
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902545A external-priority patent/AU2017902545A0/en
Application filed by University of South Australia, Monash University, Royal Melbourne Institute of Technology, College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin filed Critical University of South Australia
Publication of CN119548615A publication Critical patent/CN119548615A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202411599223.4A 2017-06-30 2018-06-29 一种治疗方法 Pending CN119548615A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2017902545A AU2017902545A0 (en) 2017-06-30 A method of treatment
AU2017902545 2017-06-30
PCT/AU2018/050667 WO2019000045A1 (en) 2017-06-30 2018-06-29 METHOD OF TREATMENT
CN201880056934.3A CN111417401A (zh) 2017-06-30 2018-06-29 一种治疗方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880056934.3A Division CN111417401A (zh) 2017-06-30 2018-06-29 一种治疗方法

Publications (1)

Publication Number Publication Date
CN119548615A true CN119548615A (zh) 2025-03-04

Family

ID=64740713

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411599223.4A Pending CN119548615A (zh) 2017-06-30 2018-06-29 一种治疗方法
CN201880056934.3A Pending CN111417401A (zh) 2017-06-30 2018-06-29 一种治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880056934.3A Pending CN111417401A (zh) 2017-06-30 2018-06-29 一种治疗方法

Country Status (6)

Country Link
US (2) US11319343B2 (https=)
EP (1) EP3645030A4 (https=)
JP (1) JP2020527546A (https=)
CN (2) CN119548615A (https=)
AU (1) AU2018293925B2 (https=)
WO (1) WO2019000045A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11319343B2 (en) * 2017-06-30 2022-05-03 Royal Melbourne Institute Of Technology Method of treatment
WO2022170396A1 (en) * 2021-02-12 2022-08-18 ViraLok Therapeutics Pty Ltd Agents and methods for therapy and prophylaxis
CN114532296B (zh) * 2021-12-14 2023-12-15 首都医科大学附属北京同仁医院 NOX2基因缺陷rd1小鼠模型及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ525914A (en) * 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
JP2005500806A (ja) * 2000-09-15 2005-01-13 コーリー ファーマシューティカル ゲーエムベーハー ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス
JP2011529967A (ja) * 2008-08-04 2011-12-15 イデラ ファーマシューティカルズ インコーポレイテッド アンチセンスオリゴヌクレオチドによるＴｏｌｌ様受容体７発現の調節
CN103153346A (zh) * 2010-06-16 2013-06-12 戴纳瓦克斯技术公司 使用tlr7和/或tlr9抑制剂的治疗方法
US20140378531A1 (en) * 2012-02-01 2014-12-25 New York University Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
US9228184B2 (en) * 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
EP3560960A1 (en) 2013-04-22 2019-10-30 The University of Tokyo Preventive or therapeutic agent for inflammatory disease
CN104211799B (zh) * 2013-05-29 2017-12-26 成都渊源生物科技有限公司 人源egf结构域蛋白及其应用
AU2014310935B2 (en) * 2013-08-21 2019-11-21 CureVac SE Combination vaccine
WO2015195947A1 (en) * 2014-06-20 2015-12-23 Yale University Compositions and methods to activate or inhibit toll-like receptor signaling
US11319343B2 (en) * 2017-06-30 2022-05-03 Royal Melbourne Institute Of Technology Method of treatment

Also Published As

Publication number Publication date
US20200216494A1 (en) 2020-07-09
US20220213143A1 (en) 2022-07-07
WO2019000045A1 (en) 2019-01-03
EP3645030A4 (en) 2021-04-21
JP2020527546A (ja) 2020-09-10
CN111417401A (zh) 2020-07-14
AU2018293925A1 (en) 2020-01-16
US11319343B2 (en) 2022-05-03
EP3645030A1 (en) 2020-05-06
AU2018293925B2 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
US12102691B2 (en) Methods for efficient delivery of therapeutic molecules in vitro and in vivo
US20240309058A1 (en) Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
KR101317100B1 (ko) 세포-침투성 펩티드로서 유용한 펩티드
WO2012090150A2 (en) New cell-penetrating peptides and uses thereof
US20220213143A1 (en) Method of treatment
US20220088131A1 (en) Compositions and methods relating to c5l2
JP2013538564A (ja) 抗ウイルス剤
US12274725B2 (en) Zika virus strains for treatment of glioma
JP7644000B2 (ja) 活性化剤
JP2021514183A (ja) 改変免疫調節ペプチド
WO2022202816A1 (ja) ペプチド及びペプチドを含む組成物
CN103025341B (zh) 胰岛素样生长因子1受体结合肽
CN107406513B (zh) 双链分子(bipartite)及其于治疗异常蛋白聚集的用途
WO2025059165A1 (en) Methods of use for rhamm-derived peptides and rhamm-derived peptide mimetics
CN113993884A (zh) 抑制呼吸道合胞病毒感染的生物及合成分子
WO2021237100A1 (en) Methods of targeting extracellular vesicles to lung
JP2022545765A (ja) 中間径フィラメント由来ペプチドおよびその使用
US20240182526A1 (en) Compositions and methods for modulting inflammatory and degenerative disorder
Vanover Molecular Toolbox for Characterizing, Preventing, and Treating Human Respiratory Syncytial Virus Infections
WO2018190713A1 (en) Inhibitors of lysine methyltransferase for treatment of pain
JP2021534826A (ja) がんの処置のためのペプチド治療薬およびその使用
Sundaram Expression And Function Of Human IkappaBzeta In Lung Inflammation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination